

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 64

Published Online August 8, 2022

Online  
Article

IN THIS ISSUE

COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (*Evusheld*)

### Important Copyright Message

**FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS**

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 64

Published online August 8, 2022

Online  
Article

### IN THIS ISSUE

**COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (*Evusheld*)**

### COVID-19 UPDATE

#### Dosing Interval for Tixagevimab/ Cilgavimab (*Evusheld*)

The FDA has amended its Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (*Evusheld* – AstraZeneca) to recommend repeat dosing every 6 months in patients who require ongoing protection against COVID-19.<sup>1</sup> *Evusheld* is authorized for IM pre-exposure prophylaxis of COVID-19 in persons  $\geq 12$  years old who weigh  $\geq 40$  kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise.<sup>2</sup>

The revision was based on pharmacologic modeling data, which suggest that tixagevimab and cilgavimab retain activity against currently circulating variants of SARS-CoV-2 (including the Omicron variants BA.2, BA.2.12.1, BA.4, and BA.5) for 6 months after administration of a 300-mg dose of each antibody.<sup>2</sup>

The recommended dosage of *Evusheld* is 300 mg of tixagevimab and 300 mg of cilgavimab given as two consecutive IM injections once every 6 months. Patients should be monitored for at least 1 hour after administration. *Evusheld* should not be used for treatment or post-exposure prophylaxis of COVID-19, or within 2 weeks after administration of a COVID-19 vaccine.<sup>2</sup> ■

1. FDA. FDA authorizes revisions to *Evusheld* dosing. June 29, 2022. Available at: <https://bit.ly/3K5AcNc>. Accessed July 11, 2022.

2. FDA. Fact sheet for health care providers: Emergency Use Authorization for *Evusheld* (tixagevimab co-packaged with cilgavimab). June 2022. Available at: <https://bit.ly/3IWpQjg>. Accessed July 11, 2022.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

#### Address:

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

#### Customer Service:

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: custserv@medicalletter.org

#### Permissions:

To reproduce any portion of this issue,  
please e-mail your request to:  
permissions@medicalletter.org

#### Subscriptions (US):

1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

#### Site License Inquiries:

E-mail: SubQuote@medicalletter.org  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected:    

Copyright 2022. ISSN 0025-732X

The  
Medical  
Letter